ClinicalTrials.gov record
Recruiting Phase 2 Interventional

Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

ClinicalTrials.gov ID: NCT05168163

Public ClinicalTrials.gov record NCT05168163. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 10, 2026, 12:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Randomized Study of Atezolizumab Plus Multi-Kinase Inhibitor Versus Multi-Kinase Inhibitor Alone in Subjects With Unresectable, Advanced Hepatocellular Carcinoma Who Previously Received Atezolizumab Plus Bevacizumab

Study identification

NCT ID
NCT05168163
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Academic and Community Cancer Research United
Other
Enrollment
122 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 26, 2022
Primary completion
Dec 30, 2025
Completion
Dec 30, 2026
Last update posted
Sep 15, 2025

2022 – 2026

United States locations

U.S. sites
16
U.S. states
12
U.S. cities
14
Facility City State ZIP Site status
Mayo Clinic in Arizona Scottsdale Arizona 85259 Recruiting
Mayo Clinic in Florida Jacksonville Florida 32224-9980 Withdrawn
Cleveland Clinic Weston Florida Weston Florida 33331 Withdrawn
University of Chicago Comprehensive Cancer Center Chicago Illinois 60637 Not yet recruiting
Carle Cancer Center NCI Community Oncology Research Program Urbana Illinois 61801 Recruiting
University Medical Center New Orleans New Orleans Louisiana 70112 Recruiting
Michigan Cancer Research Consortium NCORP Ann Arbor Michigan 48106 Recruiting
University of Michigan Comprehensive Cancer Center Ann Arbor Michigan 48109 Not yet recruiting
Mayo Clinic in Rochester Rochester Minnesota 55905 Recruiting
Roswell Park Cancer Institute Buffalo New York 14263 Recruiting
Duke University Medical Center Durham North Carolina 27710 Completed
University Hospitals Cleveland Medical Center Cleveland Ohio 44106 Withdrawn
Allegheny General Hospital Pittsburgh Pennsylvania 15212 Recruiting
Rapid City Regional Hospital Rapid City South Dakota 57701 Recruiting
Froedtert and the Medical College of Wisconsin LAPS Milwaukee Wisconsin 53226 Recruiting
Medical College of Wisconsin Milwaukee Wisconsin 53226 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05168163, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 15, 2025 · Synced May 10, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05168163 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →